Gilead Sciences : GILD

All Gilead Sciences Articles

732 Articles

Jon C. Ogg | Jan 26, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

The top analyst upgrades, downgrades and other research calls from Friday include Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead Sciences,…

Chris Lange | Jan 25, 2018 at 10:05 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The January 12 short interest data have been compared with the previous report, and short interest moves in the selected…

Jon C. Ogg | Jan 17, 2018 at 4:15 PM EST

Beyond Apple Repatriation: 16 US Corporate Giants Have $1 Trillion in Cash

Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it…

Jon C. Ogg | Jan 16, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli Lilly, Gilead, Micron, NVIDIA, P&G, Qualcomm and More

The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences,…

Chris Lange | Jan 11, 2018 at 9:50 AM EST

Short Sellers Grow More Selective on Major Biotechs

The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech…

Chris Lange | Jan 5, 2018 at 11:15 AM EST

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…

Lee Jackson | Dec 31, 2017 at 10:15 AM EST

Analysts Have 12 Top Biotech Picks for Big Upside in 2018

There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be…

Chris Lange | Dec 28, 2017 at 9:05 AM EST

Major Biotechs See Surge in Short Interest

The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech…

Jon C. Ogg | Dec 20, 2017 at 9:05 AM EST

Top Analyst Upgrades and Downgrades: Alcoa, Extreme Networks, Gilead, MGIC, Micron, Noble Energy, Twitter, US Steel, Wendy’s and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Alcoa, Extreme Networks, Gilead Sciences, MGIC, Micron, Noble…

Chris Lange | Dec 12, 2017 at 10:10 AM EST

Major Biotechs See Rising Tide in Short Interest

The November 30 short interest data have been compared with the previous report, and short interest in most of the…

Lee Jackson | Dec 11, 2017 at 9:50 AM EST

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for…

Jon C. Ogg | Dec 6, 2017 at 10:05 AM EST

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Jon C. Ogg | Nov 30, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Amazon, Barrick Gold, Boston Scientific, Chipotle, Gap, Gilead, Goldcorp, Workday and More

The top analyst upgrades, downgrades and other research calls from Thursday include Amazon, Barrick Gold, Boston Scientific, Chipotle Mexican Grill,…

Chris Lange | Nov 13, 2017 at 1:30 PM EST

Why Argus Is Taking a Step Back on Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded…

Jon C. Ogg | Nov 13, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

The top analyst upgrades, downgrades and other research calls from Monday include Best Buy, Equifax, Gilead Sciences, MongoDB, NVIDIA, Rio…

1 … 17 18 19 20 21 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

Short Sellers Raise the Stakes in Major Biotechs

Beyond Apple Repatriation: 16 US Corporate Giants Have $1 Trillion in Cash

Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli Lilly, Gilead, Micron, NVIDIA, P&G, Qualcomm and More

Short Sellers Grow More Selective on Major Biotechs

Meet Merrill Lynch’s Top Biotech Picks for 2018

Analysts Have 12 Top Biotech Picks for Big Upside in 2018

Major Biotechs See Surge in Short Interest

Top Analyst Upgrades and Downgrades: Alcoa, Extreme Networks, Gilead, MGIC, Micron, Noble Energy, Twitter, US Steel, Wendy’s and More

Major Biotechs See Rising Tide in Short Interest

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Top Analyst Upgrades and Downgrades: Amazon, Barrick Gold, Boston Scientific, Chipotle, Gap, Gilead, Goldcorp, Workday and More

Why Argus Is Taking a Step Back on Gilead Sciences

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

Short Sellers Raise the Stakes in Major Biotechs

Beyond Apple Repatriation: 16 US Corporate Giants Have $1 Trillion in Cash

Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli Lilly, Gilead, Micron, NVIDIA, P&G, Qualcomm and More

Short Sellers Grow More Selective on Major Biotechs

Meet Merrill Lynch’s Top Biotech Picks for 2018

Analysts Have 12 Top Biotech Picks for Big Upside in 2018

Major Biotechs See Surge in Short Interest

Top Analyst Upgrades and Downgrades: Alcoa, Extreme Networks, Gilead, MGIC, Micron, Noble Energy, Twitter, US Steel, Wendy’s and More

Major Biotechs See Rising Tide in Short Interest

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Top Analyst Upgrades and Downgrades: Amazon, Barrick Gold, Boston Scientific, Chipotle, Gap, Gilead, Goldcorp, Workday and More

Why Argus Is Taking a Step Back on Gilead Sciences

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings